Target intelligence / Profile preview

Synaptotagmin-12 (SYT12)

Target
SYT12
Molecular classification
Other (C2 domain–containing membrane-trafficking protein), Synaptic vesicle protein
01

Overview

Synaptotagmin-12 (SYT12) is a membrane-trafficking protein belonging to the synaptotagmin family, localized to synaptic vesicles in neurons[1][2]. Unlike classical synaptotagmin isoforms, SYT12 does not bind calcium and instead acts as a phosphoprotein regulated by phosphorylation through cAMP-dependent protein kinase A at serine 97[1][2][3][4]. SYT12 forms a complex with synaptotagmin-1, preventing synaptotagmin-1 from interacting with SNARE complexes and thereby selectively increasing spontaneous neurotransmitter release without affecting evoked release[1][2][4]. Beyond neuronal roles, increased SYT12 expression has been implicated in the progression of certain cancers such as lung adenocarcinoma, in part through activation of the PI3K/AKT/mTOR signaling pathway[1][5][3]. The gene is also involved in presynaptic forms of synaptic plasticity, such as mossy-fiber long-term potentiation in the hippocampus, through PKA-dependent signaling[4]. SYT12 is being investigated as a potential therapeutic target, especially in the context of cancer[1][5].

Other names
Synaptotagmin XIISYTXIISYT11SytXIISRG1sytXIIsynaptotagmin-XIIsynaptotagmin-12synaptotagmin XII
02

Mechanism of action

Modulation of spontaneous neurotransmitter release (via cAMP/PKA-mediated phosphorylation); Regulation of PI3K/AKT/mTOR signaling in oncogenic contexts

03

Biological functions

Regulates spontaneous synaptic vesicle exocytosisModulates neurotransmitter releaseInvolved in cAMP/PKA-dependent protein phosphorylationMay participate in cell proliferation and migration in cancer
04

Disease associations

Cancer (notably lung adenocarcinoma)Neurodegenerative disease (ex: potential association with Parkinson's)Other (role in synaptic plasticity dysfunction)
05

Safety considerations

None reported specific to SYT12 targeting; potential risks associated with synaptic transmission modulation or cancer pathways should be considered
06

Biomarkers

Elevated expression in lung adenocarcinoma correlates with tumor stage and prognosis

Beyond the preview

Go deeper on Synaptotagmin-12 (SYT12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synaptotagmin-12 (SYT12).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call